Roth Capital Resumes Arcturus Therapeutics (ARCT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Price: $9.54 +0.53%
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Roth Capital analyst Elemer Piros resumes coverage on Arcturus Therapeutics (NASDAQ: ARCT) with a Buy rating and a price target of $77.00.
For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.
Shares of Arcturus Therapeutics closed at $53.17 yesterday.
You May Also Be Interested In
- Freedom Broker Starts MNTN Inc (MNTN) at Buy
- Oppenheimer Starts Retension Pharmaceuticals (RTSN) at Outperform
- Macquarie Starts YTL Power International (YTLP:MK) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
